Podcasts about disease progression

Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS specialists should ask themselves 3 important questions when considering a patient's treatment plan. Dr. Freeman is the Director of the Multiple Sclerosis and Neuroimmunology Center at Dell Medical School at the University of Texas at Austin, where she also leads the MS and Neuroimmunology fellowship program and the MS Imaging and Outcomes Research Laboratory.  We'll also tell you about study results that reveal two distinct biologically-informed MS subtypes. We're explaining some of the confusing background to the FDA's decision not to approve a disease-modifying therapy that achieved positive results in its Phase 3 clinical trial. And did we really need a study to tell us that people living with MS fear experiencing a relapse or disease progression? Well, yes. We'll explain why. We're also reminding you to mail your insurance premium payments and other important documents earlier than you have in the past.  And we're sharing details about the two clinical trials that received $4.1 million in funding as part of the International Progressive MS Alliance Experimental Medicine Trial Awards. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: 3 questions your neurologist should be asking themselves  :22 Public Service Announcement: How the new rule about postmarks could affect your healthcare  1:16 FDA says it's not ready to approve Tolebrutinib  3:16 Study identifies two biologically-informed MS subtypes  6:29 Study results remind us that people with MS fear relapse and progression  10:09 The International Progressive MS Alliance invests $4.1 million in two clinical trials  14:04 Dr. Leorah Freeman discusses why neurologists need to ask themselves 3 important questions when considering a patient's treatment plan  17:18 Share this episode  33:16 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/436 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com The Multiple Sclerosis Insider https://themultiplesclerosisinsider.substack.com STUDY: Combined Magnetic Resonance Imaging and Serum Analysis Reveals Distinct Multiple Sclerosis Types https://academic.oup.com/brain/article/148/12/4578/8321558 STUDY: Fear of Disease Progression and Relapse in Multiple Sclerosis: A Systematic Scoping Review https://frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1680781/full JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 436 Guests: Dr. Leorah Freeman Privacy Policy

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein, it's a bit of a word salad, but what we're trying to achieve here is finding unique binding sites on proteins that are sort of away from the active site of that protein." "So, a lot of physics calculations go into these binding site calculations. The idea is to complete these quickly during the screening of hundreds or thousands of compounds. This process takes 10 to 15 minutes to run a set of computations and determine if a particular molecule is a fit for a specific protein. If that takes 10 or 15 minutes per compound, it's not a very big deal to go to that library if you need to get through billions, trillions of those compounds, and you need that computational speed to really fire up." "We are able to speed up those calculations from, let's say, 10 minutes to milliseconds. You can screen through much larger numbers of compounds and potentially even construct new molecules that are not known to the public domain, which would be a real key innovation." "What we think we have in our lead program, which is GT-02287, another molecule that was discovered through our application of Magellan. What we hope we have in GT-02287 is a disease-modifying approach to Parkinson's. Up until now, the only available treatments for Parkinson's are really just focused on the symptoms and allaying the severity of the symptoms." #Parkinsons #ParkinsonsDisease #AI #DrugDiscovery #GAINtherapeutics #DiseaseModification gaintherapeutics.com Download the transcript here

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein, it's a bit of a word salad, but what we're trying to achieve here is finding unique binding sites on proteins that are sort of away from the active site of that protein." "So, a lot of physics calculations go into these binding site calculations. The idea is to complete these quickly during the screening of hundreds or thousands of compounds. This process takes 10 to 15 minutes to run a set of computations and determine if a particular molecule is a fit for a specific protein. If that takes 10 or 15 minutes per compound, it's not a very big deal to go to that library if you need to get through billions, trillions of those compounds, and you need that computational speed to really fire up." "We are able to speed up those calculations from, let's say, 10 minutes to milliseconds. You can screen through much larger numbers of compounds and potentially even construct new molecules that are not known to the public domain, which would be a real key innovation." "What we think we have in our lead program, which is GT-02287, another molecule that was discovered through our application of Magellan. What we hope we have in GT-02287 is a disease-modifying approach to Parkinson's. Up until now, the only available treatments for Parkinson's are really just focused on the symptoms and allaying the severity of the symptoms." #Parkinsons #ParkinsonsDisease #AI #DrugDiscovery #GAINtherapeutics #DiseaseModification gaintherapeutics.com  Listen to the podcast here

When an unexpected heart murmur shows up, you may not have a specialist on speed dial, but you can have their advice in your back pocket. In this episode of the Partner Podcast, cardiologists John Bonagura and Theresa DeFrancesco share real-world advice on how to detect, stage, and manage myxomatous mitral valve disease. Listen in for practical strategies to deploy the next time you're faced with the unexpected on the other end of the stethoscope. Sponsored by Boehringer IngelheimContact us:Podcast@instinct.vetWhere to find us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/X: @cliniciansbriefInstagram: @clinicians.brief The Team:Beth Molleson, DVM - HostSarah Pate - Producer & Project Manager, Brief StudioTaylor Argo - Podcast Production & Sound Editing

This episode of Don't Miss a Beat centers on the evolving treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM) with special guest Ahmad Masri, MD. Hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Steve Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, are joined by Masri, who serves as the director of the HCM and Amyloid Program at Oregon Health & Science University, to discuss the rapid therapeutic advances in ATTR-CM and the emerging questions shaping real-world clinical practice. Masri reviews the progression from a previously untreatable disease to one now managed with three US Food and Drug Administration (FDA)-approved disease-modifying agents: tafamidis (VYNDAMAX), acoramidis (Attruby), and vutrisiran (AMVUTTRA). He highlights the tafamidis approval in 2019 as a landmark in the field, showing a substantial survival benefit in the ATTR-ACT trial, followed by similar results from acoramidis, which received approval in late 2024, in ATTRibute-CM. Vutrisiran, a TTR gene silencer approved by the FDA in March 2025, represents a mechanistically distinct approach validated in the HELIOS-B trial. Despite these advances, Masri notes that patients with late-stage disease derive limited symptomatic benefit and that residual risk remains high, even with treatment. The conversation explores whether stabilizers and silencers can or should be combined, with Masri urging caution, citing the absence of clinical data demonstrating additive benefit and warning against assumptions of harmony without clinical evidence. Masri indicated ongoing trials, such as CARDIO-TTRansform, may offer clarity on this issue. Without direct comparisons between therapies, treatment selection often hinges on patient preference, delivery method, pill burden, and payer coverage. In practice, clinicians rely on pharmacodynamic markers, like changes in TTR levels, to assess treatment effect and adjust therapy accordingly. Masri emphasizes that while ATTR-CM trials may not show improvements in quality-of-life scores, slowing disease progression remains a critical and meaningful endpoint in this severe, high-mortality condition. Looking ahead, the panel discusses the next wave of therapeutic innovation. Multiple trials are now testing agents that aim to clear amyloid from the myocardium, including NI006 (ALXN2220), PRX004, and AT-02. These immune-modulating treatments are designed for long-term use and may complement stabilizers or silencers in patients with established amyloid burden. The episode closes with a discussion on prevention. For patients with asymptomatic cardiac involvement, current therapies halt disease progression entirely in many cases. For those with pathogenic TTR variants but no overt disease, surveillance is the current standard. However, Masri introduces the ACT Early trial, which will test whether early treatment with acoramidis can prevent the onset of clinical disease in high-risk individuals, potentially reshaping the paradigm of ATTR-CM care. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Key Episode Timestamps 00:00:00 Introduction and Guest Introduction 00:00:52 Current State of Amyloid Therapeutics 00:03:41 Introduction of New Stabilizers and Silencers 00:06:05 Combination Therapy and Clinical Data 00:10:36 Choosing Therapy for Patients 00:16:40 Disease Progression and Clinical Trials 00:20:28 Pipeline and Future Therapies 00:23:51 Preventative Therapy and Asymptomatic Patients 00:27:19 Conclusion and Future Directions

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA by The Immune-Mediated Inflammatory Disease Forum

In this podcast, Dr. Valentin Fuster reviews the impact of catheter ablation on atrial fibrillation progression, summarizing a state-of-the-art article published in JACC. It explores how catheter ablation modifies the disease's mechanisms, reduces progression to persistent atrial fibrillation, and improves cardiovascular outcomes, suggesting that earlier intervention leads to better long-term results.

Prof. Sarah Camargos interviews Prof. Sun Ju Chung about his recent paper in the Movement Disorders Journal investigating diagnostic and prognostic capabilities of measuring blood mitochondrial DNA copy number (mtDNA-CN) for Parkinson's disease. Journal CME is available until March 3, 2026 Read the article.

Osteosarcoma Webinar Series: Sowmya Ramesh, PhD joins us on OsteoBites to discuss how multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression.Bone pain is a hallmark of bone cancers, including osteosarcoma (OS), mediated by skeletal-innervating peripheral afferent neurons. However, the roles of tumor-associated sensory neurons in OS beyond pain perception remain poorly understood. To investigate their regulatory functions, a chemical-genetic approach was employed in mice carrying a knock-in allele for TrkA to perturb sensory nerve innervation during OS growth and progression. TrkA inhibition in these transgenic mice significantly reduced sarcoma-associated sensory innervation and vascularization, altered tumor-associated macrophage polarization, decreased tumor growth and metastasis, and extended overall survival.These findings suggest that targeting pathological innervation in OS may serve as an adjunctive therapy to enhance clinical outcomes and survival.Dr. Ramesh is a postdoctoral researcher from the James lab at Johns Hopkins. The lab's research focus lies at the intersection of skeletal pathophysiology and stem cell biology. The lab looks at the interaction of nerves in various musculoskeletal repair including bone repair and regeneration, osteoprogenitor cell characterization, and neoplastic bone. Dr. Ramesh specifically works on understanding how peripheral nerves regulate osteosarcoma disease progression.

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

In this episode of The MSing Link Podcast, I delve into the critical healthcare barriers faced by those with multiple sclerosis, focusing on the nuances of SPMS (Secondary Progressive Multiple Sclerosis) diagnosis, MS medications, and access to physical therapy. As a physical therapist specializing in MS, I share insight into new MS drugs, the complexities of navigating insurance, and the importance of ongoing physical therapy. Tune in to uncover strategies to navigate these challenges and improve your quality of life. Don't miss our deep dive into MS healthcare obstacles and innovative therapy solutions. Resources mentioned in this episode: The MSing Link Podcast, Episode 178, Smoldering MS & Disease Progression with Dr. Gabriel Pardo, M.D. - Apple || Spotify The MSing Link Podcast, Episode 196, Reversing MS Damage: The Promising Potential of PIPE-307 to Regrow Myelin - Apple || Spotify Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Listen in as Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss current trends in and risk factors for progression to severe COVID-19, including for those for whom COVID-19 is not their primary concern when presenting to the emergency department (ED). Key topics of discussion include: How to complete a comprehensive patient workup in the EDConsiderations regarding pulse oximetryRisk stratification—what places patients at higher risk of severe disease?A detailed patient case to illustrate key takeawaysPresenters:Stephen Cantrill, MD, FACEP​Associate Director and Medical Director (Retired) ​Department of Emergency Medicine​Denver Health Medical Center​Associate Professor ​Department of Emergency Medicine​University of Colorado Health Sciences Center​Denver, ColoradoRajesh T. Gandhi, MD​Massachusetts General Hospital​Professor of Medicine​Harvard Medical School​Boston, MassachusettsPayal K. Patel, MD, MPH, FIDSA​Systemwide Director of Antimicrobial Stewardship​Associate Professor, Division of Infectious Diseases​Intermountain Health​Salt Lake City, UtahLink to full program:https://bit.ly/4fs7HcbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/management-of-her2-low-mbc-following-first-line-disease-progression/29834/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations. Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/management-of-her2-low-mbc-following-first-line-disease-progression/29834/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations. Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

Listen in as Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss best practices in treating patients hospitalized with mild to moderate COVID-19, including: Current guidelines from the Infectious Diseases Society of America and National Institutes of Health How to optimize therapy selection based on patient risk factors, including key data supporting best practicesA detailed patient case to illustrate key takeawaysPresenters:Stephen Cantrill, MD, FACEP​Associate Director and Medical Director (Retired) ​Department of Emergency Medicine​Denver Health Medical Center​Associate Professor ​Department of Emergency Medicine​University of Colorado Health Sciences Center​Denver, ColoradoRajesh T. Gandhi, MD​Massachusetts General Hospital​Professor of Medicine​Harvard Medical School​Boston, MassachusettsPayal K. Patel, MD, MPH, FIDSA​Systemwide Director of Antimicrobial Stewardship​Associate Professor, Division of Infectious Diseases​Intermountain Health​Salt Lake City, UtahLink to full program: https://bit.ly/4fs7HcbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

CME credits: 0.75 Valid until: 17-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-peer-discussion-integrating-novel-her3-directed-adcs-upon-disease-progression-following-egfr-tki-and-platinum-chemotherapy/26455/ Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn. This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.

CME credits: 0.75 Valid until: 17-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-peer-discussion-integrating-novel-her3-directed-adcs-upon-disease-progression-following-egfr-tki-and-platinum-chemotherapy/26455/ This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

In this episode, Dr. Valentin Fuster discusses groundbreaking research on the interplay between cardiovascular risk factors and chronic kidney disease (CKD) progression among Chinese adults. Highlighting a study that reveals how effective management of hypertension, cholesterol, and blood glucose can significantly reduce the risks of cardiovascular events and mortality in CKD patients, the conversation emphasizes the crucial need for targeted treatment strategies to improve patient outcomes.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/a-practical-guide-to-prescribing-in-hf/27019/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/level-up-your-skills-tailoring-management-of-hf/27021/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/hf-management-for-patients-with-comorbid-conditions/27020/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/partnering-with-patients-building-effective-communication-and-support-in-hf-care/27018/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

CME credits: 0.75 Valid until: 15-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/earlier-is-better-identifying-and-diagnosing-hf-early-in-disease-progression/27017/ Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings. This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Niccolo Maurizi from Lausanne, Switzerland. They discuss his recent paper in Heart on a Swiss Fabry's regsitry. If you enjoy the show, please leave us a podcast review at https://itunes.apple.com/gb/podcast/heart-podcast/id445358212?mt=2 or wherever you get your podcasts - it's really helpful. Link to published paper: https://heart.bmj.com/content/early/2024/05/15/heartjnl-2024-323975

In this episode (you can watch on YouTube here!), we explore the potential of Hyperbaric Oxygen Therapy (HBOT) as a treatment to prevent the progression of Parkinson's Disease. HBOT involves breathing pure oxygen in a pressurized environment, which is believed to enhance the body's natural healing processes. But can it really slow down or even halt the progression of Parkinson's Disease?  We'll highlight: -What is Hyperbaric Oxygen Therapy and how does it work? -The science behind HBOT and its effects on brain health. -Current research and case studies on HBOT's impact on Parkinson's Disease. -Potential benefits and risks of using HBOT for Parkinson's patients. Join us as we explore this promising yet controversial treatment and what it could mean for the future of Parkinson's care. Don't forget to like, subscribe, and hit the notification bell for more videos on Parkinson's Disease treatments and research! Resources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138219/  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851727/ https://www.parkinsonsresource.org/news/articles/parkinsons-and-hyperbaric-oxygen-therapy/ Help to support this channel and out efforts to educate the world about Parkinson's Disease and get access to personalized content:  https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join  https://www.patreon.com/pdeducation Please be sure to give support to our sponsors: Comfort Linen (15% off entire order when applying the code PARKINSONSDISEASEEDUCATION at checkout) Kizik Shoes Orthofeet If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013 Medical Disclaimer: All information, content, and material of this podcast is for informational purposes only and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.  Affiliate disclaimer: Keep in mind that links used for recommended products may earn me a commission when you make purchases. However, this does not impact what products I recommend. If I recommend a specific product it is because it has been vetted by myself or based on personal use #parkinson #parkinsonsawareness #parkinsonsdisease #parkinsons #hyperbaricoxygentherapy #hyperbaricoxygen #mitochondria #oxidativestress

Welcome to our newest podcast series dedicated to preventing breast cancer recurrence and disease progression. In this opening episode, we dive deep into understanding what a cancer recurrence means and explore practical steps to reduce our risk. We'll share insights and personal experiences to empower you on your journey toward sustained health and resilience. Join us as we discuss evidence-based strategies, lifestyle changes, and the mental and emotional aspects of managing your health after a breast cancer diagnosis.

This week, Dr. Kahn packs a lot of practical information on health and longevity into this "pea-cast." He discusses the longevity plan of Dr. Michael Roizen, a well-known physician and author, including his regular use of the Prolon Fasting Mimicking Diet (www.prolonfmd.com/drkahn). Another study examines the lifestyle habits of the ultra-elderly in China, showing that it matters even at that age to adhere to healthy habits. The importance of mitral annular calcification (MAC) is also presented. Additionally, two controversial topics—cholesterol levels and mortality, as well as protein intake and kidney disease—are discussed. The major topic is the importance of Lipoprotein(a) genetic cholesterol levels and disease progression, both in the coronary arteries and on the aortic valve. You do not want to miss this discussion of great importance for all.

Dr. Michele Matarazzo interviews Dr. Olivier Rascol on the results of the clinical trial recently published in the New England Journal of Medicine. Tune in to learn about the mechanisms of action and potential of lixisenatide and other GLP-1 receptor agonists in impacting the progression of Parkinson's disease. Read the article »

HEALTH NEWS   ·         Plant-Based Diets and Disease Progression in Men With Prostate Cancer ·         Daily Bathing in Bicarbonate Water Baths Improves Stress, Sleep, and Immune Function ·         A sum greater than its parts: Time-restricted eating and high-intensity exercise work together to improve health ·         Brief anger may impair blood vessel function, says new research ·         The Impact of Curcumin, Resveratrol, and Cinnamon on Modulating Oxidative Stress and Antioxidant Activity in Type 2 Diabetes ·         Study shows green views lead to healthier food choices

Dr. Elie Jarrouge is a returning guest on our show! Check out his first appearance on episode 133 of Boundless Body Radio! Dr. Elie Jarrouge is a medically trained hospitalist and had worked in hospital medicine from 2013 until 2022, when he started working at his own practice full-time. Dr. Jarrouge has seen firsthand the advanced complications of chronic metabolic diseases, such as obesity, diabetes, NAFLD, heart disease, stroke, dementia, and autoimmune disease. After watching conventional treatments for chronic disease fail his patients for many years, and after suffering from his own health issues, he decided to do his own research and blaze his own path. He realized that the treatment is not more pills but rather fix the root cause, which revolves around food. He eventually used a low carbohydrate lifestyle with his own health to lose 35 Ibs, reverse his hypertension and insulin resistance, and cure his lower back pain. He now helps people reclaim their health by coaching them through lifestyle changes and helps deprescribe medications. He currently practices medicine remotely via telemedicine! Find Dr. Elie Jarrouge at-https://www.metabolichealthmd.com/ TW- @ElieJarrougeMDIG- @elie_jarrougeEmail- Elie@metabolichealthmd.comFind Boundless Body at- myboundlessbody.com Book a session with us here!

Today, I have the honor of interviewing Dr. Gabriel Pardo. He is a physician and a scientist that aims to provide comprehensive care to individuals with MS through a multidisciplinary approach. On today's episode, we talk about smoldering MS, new terminology that explains worsening of function without changes on an MRI, aging out of disease modifying therapies and the effects of BTK inhibitors. Dr. Gabriel Pardo is a physician and a scientist that aims to provide comprehensive care to individuals with Multiple Sclerosis through a multidisciplinary approach while also participating in clinical research. He is the Director Oklahoma Medical Research Foundation Multiple Sclerosis Center of Excellence. Connect with Dr. Pardo: Website: https://omrf.org/ Twitter: @docforms Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

In this episode of the Healthy, Wealthy, and Smart podcast, host Dr. Karen Litzy is joined by Dr. Mani Kukreja (MD, MPH, IIN), Entrepreneur and Founder of Integrative Health and Wellness Practice Livagewell, to discuss the hot topic of aging well.   Dr. Kukreja shared her personal journey from conventional medicine to a more holistic approach, driven by her own experience with Hashimoto's autoimmune thyroiditis. She emphasized the importance of addressing the root causes of diseases rather than just treating symptoms.   We discussed the multifaceted nature of aging, which Dr. Kukreja defines as a progressive decline in biological functions leading to increased disease risk and reduced lifespan. She debunked the myth that aging is solely determined by genetics, highlighting that lifestyle and environmental factors play a significant role.   Dr. Kukreja provided valuable insights into the processes of oxidation, inflammation, and detoxification in our bodies, explaining how they contribute to aging and the onset of age-related diseases. She stressed that while we cannot stop aging, we can certainly influence how we age by managing these biological processes.   Time Stamps:  00:00:02 - Introduction to the Podcast 00:00:13 - Topic of Aging Introduced 00:00:36 - Guest Introduction: Dr. Mani Kukreja 00:01:08 - Dr. Mani's Background and Interest in Aging 00:02:16 - Dr. Mani's Personal Health Journey and Approach 00:04:36 - Dr. Mani's Experience with Her Father's Health 00:05:08 - Clinical Research Insights on Disease Progression 00:06:18 - Launching Live Age Well Practice 00:06:29 - Defining Holistic Health 00:08:03 - The Aging Industry and Control Over Aging 00:10:03 - Theories and Control of Aging 00:11:09 - Biological Age vs. Chronological Age 00:13:09 - Genetic and Lifestyle Factors in Aging 00:15:18 - Environmental Toxins and Aging 00:16:59 - Addressing Aging in Less Ideal Environments 00:20:43 - Importance of Knowledge and Self-Care 00:21:04 - Supplements and Their Claims 00:23:07 - Proprietary Blends in Supplements 00:24:05 - Frozen Fruits and Vegetables as an Option 00:25:32 - Reducing Biological Age 00:27:10 - Biological Age Explained 00:28:04 - Factors to Improve Biological Age 00:29:33 - Understanding Oxidation in the Body 00:33:08 - The Processes of Aging: Oxidation, Inflammation, Detoxification 00:37:11 - Solutions to Improve Biological Age 00:39:43 - Importance of Sleep in Aging 00:44:35 - Exercise as the Elixir of Youth 00:47:03 - Exercise and Brain Health 00:49:27 - Role of Supplements in Aging   More About Dr. Mani Kukreja: Dr. Mani Kukreja (MD, MPH, IIN) is an integrative health and wellness expert and the founder/CEO  of  Livagewell. She has extensive experience helping her clients optimize their overall health, including metabolic, skin, gut, and immune health.     Mani is a health, wellness, and lifestyle influencer, biohacker, and health advocate who is always on a quest to bio-optimize Health and Aging to live a balanced and sustainable life.    Mani is also an ambassador to a few health-optimizing supplement brands that she truly believes in values.    Dr Mani has authored several high-impact publications in peer-reviewed clinical research journals in the medical and wellness field throughout her career.      Resources from this Episode: LivAgeWell Website Dr. Mani on Instagram Clear Skin Chronicles Intentionally Well Podcast   Jane Sponsorship Information: Book a one-on-one demo here Mention the code LITZY1MO for a free month     Follow Dr. Karen Litzy on Social Media: Karen's Twitter Karen's Instagram Karen's LinkedIn   Subscribe to Healthy, Wealthy & Smart: YouTube Website Apple Podcast Spotify SoundCloud Stitcher iHeart Radio

Commentary by Dr. Valentin Fuster

Have you recently heard about Akkermansia and wondered what it's all about?   We know it's a commensal bacteria that resides in the human gut, thriving in the mucus layer, but its popularity in the wellness world has many asking: Are the benefits truly substantial?   To answer this question let's go over some common claims and what the research actually tells us.   Watch Next… These Probiotics Improve Leaky Gut by 82%: https://www.youtube.com/watch?v=CEt0kdT5AOU&t=239s  NEW Science-Backed Ways to Improve Fatigue, Insomnia, Stress: https://www.youtube.com/watch?v=kEmj83EIfyU&t=8s    Read Next:  Why Probiotic Biodiversity is More Important than Strain: https://drruscio.com/what-is-the-best-probiotic-strain/  The Best Probiotic Protocol? The Triple Therapy Approach: https://drruscio.com/triple-therapy-probiotic-protocol/    Timestamps 00:00  Intro  02:06  What is Akkermansia? 04:29  “Only strain that lives and regulates the gut lining” 05:10  “Major part of the microbiome” 06:49  “Low levels are associated with poor gut health” 07:56  “Good for metabolism & gut health”  10:30  Beware of “Positive Publication Bias” 12:14  Other probiotics that improve gut health 12:54  Increasing Akkermansia naturally 17:49  Key takeaways 18:54  Recommended protocol   Featured Studies  Akkermansia muciniphila: 18 years after its first discovery https://www.frontiersin.org/articles/10.3389/fgstr.2022.1024393/full Akkermansia muciniphila, a human intestinal mucin-degrading bacterium https://pubmed.ncbi.nlm.nih.gov/15388697/ Role of Akkermansia in Human Diseases:  https://pubmed.ncbi.nlm.nih.gov/37111034/ Akkermansia muciniphila improves glucose homeostasis https://pubmed.ncbi.nlm.nih.gov/33820962/ Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans https://pubmed.ncbi.nlm.nih.gov/34223947/ Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression https://pubmed.ncbi.nlm.nih.gov/36835309/ Gut Bifidobacteria Populations in Human Health and Aging https://pubmed.ncbi.nlm.nih.gov/27594848/ Akkermansia muciniphila in the Human GI Tract https://pubmed.ncbi.nlm.nih.gov/30041463/ Intestinal Lactobacillus in health and disease, a driver or just along for the ride? https://pubmed.ncbi.nlm.nih.gov/28866243/ Akkermansia lower in severe obesity https://pubmed.ncbi.nlm.nih.gov/31265324/ Impairment of Insulin Secretion and Glucose Homeostasis in Lean Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34085773/ Akkermansia muciniphila in IBD: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853388/ Mucosa-Associated Microbiota in Patients with IBS https://pubmed.ncbi.nlm.nih.gov/33271532/ Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease https://pubmed.ncbi.nlm.nih.gov/34884399/ Gut microbiome of MS patients https://pubmed.ncbi.nlm.nih.gov/36113426/ Probiotics fortify intestinal barrier function https://pubmed.ncbi.nlm.nih.gov/37168869/ Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in IBS https://pubmed.ncbi.nlm.nih.gov/37686889/ Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in IBD https://pubmed.ncbi.nlm.nih.gov/33555375/ Effects of probiotics on functional constipation https://pubmed.ncbi.nlm.nih.gov/32005532/ Probiotics for Preventing and Treating SIBO https://pubmed.ncbi.nlm.nih.gov/28267052/ Probiotics as an effective therapeutic approach in alleviating depression symptoms https://pubmed.ncbi.nlm.nih.gov/35348020/ Diets that differ in their FODMAP content alter the colonic luminal microenvironment https://pubmed.ncbi.nlm.nih.gov/25016597/ Prebiotic Effect on Gut With Altered FODMAP Intake in Patients with Crohn's Disease https://pubmed.ncbi.nlm.nih.gov/27077959/ Efficacy of a low FODMAP diet in IBS https://pubmed.ncbi.nlm.nih.gov/34376515/ Lipoprotein and Endotoxemia Improvement in Metabolic Syndrome with Gut Microbiota Modification https://pubmed.ncbi.nlm.nih.gov/31451009/ Regulation of gut microbiome by keto diet https://pubmed.ncbi.nlm.nih.gov/36313018/ Islamic fasting leads to an increased Akkermansia https://pubmed.ncbi.nlm.nih.gov/31854308/ Strategies to promote Akkermansia https://pubmed.ncbi.nlm.nih.gov/30416539/ Adjuvant Probiotics Attenuate Glycemic Levels and Inflammatory Cytokines in Type 1 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/35299968/   Get the Latest Updates  Facebook - https://www.facebook.com/DrRusciodc Instagram - https://www.instagram.com/drrusciodc/   DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g  *Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.

We're re-running an important episode on Alzheimer's disease — a topic that touches many people. We still don't have a complete understanding of the disease and that makes it hard to design effective therapies. In 2022, Russ Altman sat down with mechanical engineer Ellen Kuhl who offered a glimpse into the way she's using computational modeling to help improve our understanding of Alzheimer's disease.Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/XChapters:(00:00:00) Introduction Russ introduces the episode on Alzheimer's disease, highlighting its global impact, challenges treating it, and Dr. Ellen Kuhl's research on it.(00:02:08) The Approach and Research MethodsEllen Kuhl discusses her lab's interdisciplinary approach, and method of using existing data to create dynamic models to study the brain's lifecycle and degeneration in Alzheimer's disease.(00:03:46) Key Features of Alzheimer's Disease and DetectionBiomarkers of Alzheimer's, their role in brain cell death and cognitive decline, and the possibilities for early detection methods of these protein issues.(00:07:20) How Computational Models FunctionHow the models integrate various data points and physics principles to comprehensively understand Alzheimer's progression.(00:08:43) Spread of the DiseaseExploring the mechanisms of how Alzheimer's spreads from cell to cell in the brain, and the progression through the lobes of the brain, regardless of the cause genetic or trauma induced.(00:12:33) Interdisciplinary Collaboration The challenges and benefits of working as a mechanical engineer in Alzheimer's research and the opportunities of a multidisciplinary approach.(00:14:33) Alzheimer's Drug Development Modeling a controversial Alzheimer's drug, its potential impact, and the importance of early diagnosis for effective treatment.(00:16:04) Transition to COVID Research and ModelingHow the Alzheimer's model was rapidly adapated to study the spread of COVID-19, drawing parallels between brain regions and city networks.(00:18:38) Covid Modeling Learnings and ApplicationsHow their COVID models highlighted the importance of asymptomatic transmission and helped governments with reopening strategies.(00:20:24) Responsible Model Application The rampant and at times irresponsible use of  models during the pandemic, and metrics for measuring credibility of models(00:23:59) COVID Data SharingThe positive legacy of COVID-19, focusing on the accelerated progress facilitated by open and transparent data sharing.(00:24:53) Model Interpretability and ClosingInsights into the importance of model interpretability and the value of reducing complexity to enhance understanding. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/X

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

“I haven't had any medical people tell me that I shouldn't go all out,” says our protagonist in this episode, Nordic John. He's 80 years young but still competing internationally in cross-country skiing despite  the onset of Parkinson's disease a decade ago. “That is really effective when you push yourself to the limit.” Our expert guest, Dr. Jerry Vitek, Head of Neurology at the University of Minnesota Medical School,  confirms John's experience. “Exercise is one of the best things we can do and recommend to our patients.” Nordic John's wife, Gina, attests that John is no stranger to the  vigorous challenge of cross country skiing. John directed the Nordic Skiing Program at the Craftsbury Outdoor Center in Vermont for decades. And both attended the 2023 Master's World Cup of Skiing in Austria.  “I just need to get him to the start line because then when the gun goes off he just knows what to do,” she explains.  That means Nordic John's muscle memory for skiing remains intact despite the onset of other symptoms, such as tremors and loss of balance.  “There's no question that when you start to become proficient at something, you've clearly changed those connections and strengthened them,” confirms Dr. Vitek.  We'll also hear from Coach Ollie, who has taken over John's former position at the Craftsbury Center yet now directs John at his Master's practices. And we'll learn about the important role played by the actor Michael J. Fox and his foundation in raising $1 billion for Parkinson's research so far. How do John and Gina fare in disappointing snow conditions at the Master's World Cup? What important research is on the horizon for the many millions of Parkinson's patients worldwide? Tune in to learn more on this  final My Body Odyssey episode of Season Two, Nordic John on the Parkinson's Trail.  My Body Odyssey is a Fluent Knowledge production. Original music by Ryan Adair Rooney.  SHOW NOTES Experts: Jerrold Vitek, MD, PhD Studies: Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues Forced, Not Voluntary, Exercise Improves Motor Function in Parkinson's Disease Patients Resources What is Parkinson's?  Parkinson's disease: overview and symptoms Stanford Medicine: The Benefits of Exercise for PD Parkinson's Foundation: Exercise NIH: Role of Physical Activity in Parkinson's Disease American Parkinson Disease Association: Which types of exercise are best for Parkinson's? American Parkinson Disease Association: Approved Medications for Parkinson's American Association of Neurological Surgeons: Causes of Parkinson's Parkinson's Foundation: Postural Instability Stanford Medicine: The science behind muscle memory Preserved motor memory in Parkinson's disease Benefits of physical exercise on Parkinson's disease disorders induced in animal models Neurotrophic Factors Growth Factors The Relationship Between Stress, Anxiety, and Parkinson's Disease How Stress and Stress Management Impact Parkinson's Can Exercise Slow Parkinson's Disease Progression? with Daniel Corcos, PhD The Michael J. Fox Foundation For Parkinson's Research John Broadhead: VT Ski Hall of Fame, 2019 Climate change makes the future of Nordic skiing uncertain  Craftsbury Outdoor Center Ski For Parkinson's University of Michigan Udall Center of Excellence for Parkinson's Disease Research Jaxon XC Bethel Outing Club NENSA Nonstop Nordic Silver Star

Episode 106 -Preventing Periodontal Disease Progression with Closed Root Planing   This podcast explains how using a periodontal curette to perform closed root planing can prevent the progression of periodontal disease and bone loss in pets. It describes how to identify abnormal bleeding pockets around teeth and use the curette to remove inflamed tissue and allow connective tissue reattachment. Charging for closed root planing procedures can improve quality of care and prevent extractions.   Love Veterinary Dentistry?

Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that's exactly what his company is called: Better Therapeutics. Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to “help people change some of those core beliefs, which then directly influence what we do on a day to day basis.” And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors. Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions. In this episode, we cover: Patient experience using digital therapeutics for type 2 diabetes Nutritional CBT – Better Therapeutics innovative new form of Cognitive Behavioral Therapy Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps What's next in the Better Therapeutics pipeline and how these decisions are made The future of Digital Therapeutic infrastructure Guest Links and Resources: Connect with Mark Berman on LinkedIn | Twitter Visit bettertx.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Dr. Centor discusses the risk for progression of chronic kidney disease after an episode of acute kidney injury with Drs. Chi-yuan Hsu and Anthony Muiru.

In this episode, you will learn: The benefits of hyperbaric therapy in midlife How it works in the slowing of disease and aging How this works with rapid repair to your body What is HBOT Why you need this to reduce inflammation, improve circulation and more Aimee is a certified International Hyperbaric Technician by the International Board of Undersea Medicine (IBUM) and owner of Next Level Oxygen Hyperbaric MedSpa. She is formerly a product specialist for the number one manufacturer of portable hyperbaric chambers, and continues to be an authorized retailer of those products.  Aimee was introduced to HBOT in 2005 while working as the Development Director for the National Autism Association, and became a regular user of HBOT in 2015 to address auto-immune issues. When Aimee isn't helping clients improve their health and well-belng, she dedicates time to another passion, flying the friendly skies as a Flight Attendant.

Featuring perspectives from Dr Corey J Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands, including the following topics: Optimal use of front-line immune checkpoint inhibition for metastatic non-small cell lung cancer (NSCLC) (00:00) Case: A man in his late 60s with NSCLC, no actionable mutations, PD-L1 20%, who received second-line datopotamab deruxtecan as part of a clinical trial (12:29) Case: A man in his early 70s with metastatic NSCLC, PD-L1 30%, who received first-line chemotherapy with pembrolizumab followed by maintenance pembrolizumab and second-line ramucirumab/pembrolizumab after disease progression (29:29) Case: A man in his mid 60s, PD-L1 60% and no actionable mutations who received first-line single-agent pembrolizumab followed by the addition of chemotherapy and chemotherapy/immunotherapy maintenance for NSCLC (40:23) Case: A woman in her late 60s with NSCLC, PD-L1 60%, with complete response in the liver and lung to second-line tumor treating fields with atezolizumab (57:18) Current Management of NSCLC After Disease Progression on Anti-PD-1/PD-L1-Containing Regimens — Dr Langer (1:10:48) Potential Role of Novel Immunotherapy-Based Combination Strategies in Progressive Advanced NSCLC – Dr Reckamp (1:30:14) TROP2 and Novel Antibody Drug Conjugates Under Evaluation in NSCLC – Dr Sands (1:53:36) Other Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC – Dr Leal (2:18:58) CME information and select publications  

Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/RelapsedmNSCLCThinkTank2023)

Featuring perspectives from Dr Adiyta Bardia and Dr Erika Hamilton, including the following topics: Introduction: Biopharmacology and Endocrinology of Breast Cancer (0:00) Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Dr Bardia (12:15) Future Directions in the Management of ER-Positive mBC — Dr Hamilton (33:16) Clinical Investigator Survey (51:50) CME information and select publications

In this episode, CJ Walker, also known as the Genetic Diabetic, speaks about LADA (Latent Autoimmune Diabetes of Adulthood), a condition often misdiagnosed as type 2 diabetes. CJ shares her personal experience with being misdiagnosed and ultimately diagnosed with LADA and discusses the key things to know about this condition. This episode is a must-listen for anyone interested in learning more about LADA and how it differs from other types of diabetes. Listeners will gain valuable insights into this lesser-known form of diabetes and learn how to recognize the symptoms and seek appropriate care.LADA: The Diabetes That Falls in BetweenLADA, or Latent Autoimmune Diabetes of Adulthood, is a condition that is often misdiagnosed. Some people call it type 1.5 diabetes, as it shares characteristics of both type 1 and type 2 diabetes. LADA is a form of diabetes caused by an autoimmune response that attacks the insulin-producing cells in the pancreas. This results in gradually losing insulin production, leading to high blood sugar levels.One of the key differences between type 2 diabetes and LADA is the age of onset. Type 2 diabetes typically occurs in adults over the age of 45, while LADA can occur at any age but is most commonly diagnosed in adults between the ages of 30 and 50. Additionally, LADA is more common in people who are not overweight or obese, while type 2 diabetes is often associated with obesity.Advocating for Diabetes: A Never-Ending FightDiabetes is a chronic illness that requires constant advocacy; this is especially true for those with LADA, a form of diabetes that is often misdiagnosed as type 2 diabetes. CJ shares her experience of being misdiagnosed with type 2 diabetes and her frustration with ineffective treatments. It was only after advocating for herself and doing her research that CJ could receive a proper diagnosis of LADA. CJ highlights the need for individuals with diabetes to be proactive in their healthcare and not be afraid to speak up and ask questions.LADA: The Autoimmune Diabetes That Needs Careful ManagementLADA, a form of diabetes with an autoimmune origin, involves the immune system attacking healthy tissues and cells. Unlike type 1 diabetes, LADA progresses slowly and is often diagnosed in adulthood. To preserve pancreatic function and insulin production, it is important to manage LADA by minimizing stress on the pancreas. This includes avoiding processed sugars and refined flour that can trigger insulin surges. While an ultra-low-carb or keto diet isn't required, it's essential to be mindful of food choices and their impact on blood sugar levels.Key Takeaways:[00:21] LADA, Latent Autoimmune Diabetes of Adulthood[04:14] Type 1.5 diabetes diagnosis[08:27] Autoimmune conditions and proper diagnosis[14:39] Managing diabetes takes decision-making[16:39] Hormonal differences in diabetes[21:09] Latent autoimmune diabetes in adults[25:03] Managing LADA with medications[29:14] Diabetes support and resourcesResources:Website: https://thegeneticdiabeticblog.com/LinkedIn: https://www.linkedin.com/in/thegeneticdiabetic/Instagram: https://www.instagram.com/thegeneticdiabeticblog/Facebook: https://www.facebook.com/thegeneticdiabeticblog/ Support the show